Men and Women Are Running the Same Hormone Labs. That's the First Mistake.

A 38-year-old man and a 41-year-old woman walk into the same telehealth intake form. They both check "fatigue," "low libido," and "difficulty building muscle." The platform flags both for a hormone panel. The results come back, and both get handed a protocol that looks suspiciously similar to the one the platform gave the last fifty people who checked those same boxes. This is where hormone optimization goes wrong — not at the prescription stage, but at the interpretation stage.

Sex-differentiated hormone protocols have been standard in academic endocrinology since the Endocrine Society published its first sex-specific testosterone guidelines in 2006. Most commercial telehealth platforms still flatten those differences in the name of operational efficiency. Here's what the data says about running this correctly.

---

What the Reference Ranges Are Actually Telling You

The first number most patients fixate on is testosterone. For men, the Endocrine Society's clinical practice guidelines (Bhasin et al., 2018) define the normal total testosterone range as 264–916 ng/dL. For women, normal ranges run between 15–70 ng/dL — and female testosterone is almost entirely free or loosely bound, making total testosterone a poor standalone marker. Running a female patient on a men's reference range generates false reassurance or false alarm depending on the direction.

DHEA-S, estradiol, SHBG, and thyroid markers (free T3, free T4, TSH) complete the minimum picture for both sexes — but they're read differently. A woman in her late 30s with an estradiol of 30 pg/mL and normal LH is a different clinical scenario than a perimenopausal woman with the same estradiol and elevated FSH. Total testosterone, free testosterone, SHBG, and estradiol are the four-lab minimum for men; women need those plus LH, FSH, and progesterone to capture cycle-phase context if they're still menstruating.

---

Men's Protocols: Where the Dosing Errors Cluster

The most common error in male TRT isn't under-dosing — it's ignoring aromatization. Standard testosterone cypionate doses in commercial protocols run 100–200 mg/week intramuscular or subcutaneous. At the higher end of that range, a clinically significant percentage of men aromatize enough testosterone to estradiol to produce estrogenic symptoms: water retention, mood swings, reduced libido. The correct response is to retest estradiol using a sensitive assay (targeting 20–30 pg/mL in men) and adjust dose or add anastrozole at 0.25–0.5 mg twice weekly if needed — not to titrate testosterone up.

The second cluster of errors involves HCG or hCG analogs like kisspeptin, which preserve testicular function and fertility signals during TRT. Protocols that skip this are acceptable for men who've completed their families or who are clear about the tradeoff. What's not acceptable is platforms that don't disclose that standard TRT suppresses endogenous LH and FSH within four to six weeks of initiation, making fertility recovery uncertain without intervention.

For men adding a growth hormone secretagogue, ipamorelin is the standard starting point — typically dosed at 200–300 mcg before bed — because it produces a clean GH pulse without the cortisol or prolactin spike associated with GHRP-6. Tesamorelin, an FDA-approved GHRH analog, is the more targeted option for visceral fat reduction in men with that specific phenotype.

---

Women's Protocols: The Progesterone Gap

Female hormone optimization has a real evidence problem on one side and an overcorrection problem on the other. The evidence problem: the Women's Health Initiative enrolled women with a mean age of 63, which limits what those findings tell us about hormone optimization in women in their 30s and 40s. The overcorrection: in response, some clinics swing to aggressive testosterone pellet therapy with doses that push female total testosterone above 150 ng/dL, producing androgenic side effects — acne, hair thinning, voice changes — that can take 6–12 months to fully reverse after discontinuation.

The sensible middle for premenopausal or perimenopausal women starts with progesterone, specifically oral micronized progesterone (Prometrium or generic) at 100–200 mg taken at night. Synthetic progestins such as medroxyprogesterone acetate do not replicate the neurosteroid effects of natural progesterone — a 2009 randomized trial by Schüssler et al. in the journal Sleep found that oral micronized progesterone improved sleep architecture while medroxyprogesterone acetate did not. Women who've been on synthetic progestins and report poor sleep, anxiety, or mood instability should ask specifically about switching to micronized progesterone.

Female testosterone therapy, when indicated, works best delivered transdermally at low doses: testosterone cream compounded to 0.5–2 mg/day applied topically, keeping serum free testosterone within the high-normal female range of 1.0–2.2 pg/mL rather than attempting to match male levels.

---

What Commercial Platforms Get Right and Where They Fall Short

Telehealth has expanded access to panels that a GP routinely skips. A comprehensive male hormone panel — testosterone (total + free), estradiol, LH, FSH, SHBG, PSA, CBC, CMP, TSH — runs $180–$350 out of pocket at most labs in 2026. Some online hormone programs bundle baseline labs with the initial consultation fee, which changes the cost comparison.

The failure mode is follow-up. Some platforms check labs at 90 days; others have no structured recall system and rely on patients to request retesting. Protocols without a 60-day recheck built into the dose titration window are not complete protocols — they're starting points with billing attached.

System Labs has built structured monitoring into its TRT offerings for men, which separates it from single-prescription services. For broader clinic comparisons across both sexes and goals, the hormone optimization clinics directory allows filtering by services offered and patient gender.

---

The Actual Takeaway

A protocol built on a single testosterone number without SHBG, without estradiol, and without a monitoring schedule isn't optimization — it's guessing with lab stationery. The bar for an adequate protocol is specific: a baseline panel with at least six markers, sex-appropriate reference ranges, a dose titration window with a recheck at 60 days, and a clear answer to "what happens if symptoms don't improve at 90 days?" Clinics that can't answer that before you pay should be pressed until they can, or crossed off the list.

---

Peptide Clinic Finder is a comparison platform. The author may receive compensation if you sign up through links on our partner pages.

---